Last reviewed · How we verify
L-Histidine (HISTIDINE)
L-Histidine is a marketed nutritional support for infants and young children, currently without a specified revenue figure but with a key composition patent expiring in 2028. Its primary competitive advantage lies in its mechanism of action, which involves transport into cells via the Large neutral amino acids transporter small subunit 1, a unique pathway among its competitors. The primary risk to L-Histidine's market position is the presence of off-patent alternatives such as gabapentin and leucine, which may offer cost-effective substitutes for some applications.
At a glance
| Generic name | HISTIDINE |
|---|---|
| Drug class | Amino Acid [EPC] |
| Target | Large neutral amino acids transporter small subunit 1 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Nutritional Support for Infants and Young Children
- Prevent Nitrogen and Weight Loss
Common side effects
- Foetal growth restriction
Key clinical trials
- Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (PHASE1)
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- Safety and Efficacy of Faricimab in Patients With NPDR (PHASE2)
- Essential Amino Acids and Parkinsons Disease (PHASE1)
- SMART Diets for MASLD (PHASE2)
- PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS) (NA)
- To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV (PHASE1)
- Study of Intravenous ZMA001 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-Histidine CI brief — competitive landscape report
- L-Histidine updates RSS · CI watch RSS